Conquering RAS: From Biology to Cancer Therapy
Autor Asfar Azmien Limba Engleză Hardback – 7 sep 2016
The book covers topics ranging from basic RAS biology, to translational biology and drug discovery applications. These topics will be appealing to basic researchers working in labs who seek deeper understanding of the modern concepts in RAS research. On the other side, the oncologist at the patient’s bedside will find the book useful as they routinely face the daunting task of treating patients that predominantly have a disease driven by oncogenic KRAS.
- Brings together wide ranging topics in RAS basic and translational biology for the scientific and clinical communities
- Showcases recent advancements in RAS research under one comprehensive volume
- Includes video clips, color illustrations, and important website links to facilitate a clear understanding of RAS in cancer research
Preț: 680.67 lei
Preț vechi: 910.71 lei
-25% Nou
Puncte Express: 1021
Preț estimativ în valută:
130.31€ • 135.45$ • 108.04£
130.31€ • 135.45$ • 108.04£
Carte tipărită la comandă
Livrare economică 30 ianuarie-13 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128035054
ISBN-10: 0128035056
Pagini: 294
Ilustrații: illustrations
Dimensiuni: 191 x 235 x 29 mm
Greutate: 0.76 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0128035056
Pagini: 294
Ilustrații: illustrations
Dimensiuni: 191 x 235 x 29 mm
Greutate: 0.76 kg
Editura: ELSEVIER SCIENCE
Cuprins
SECTION I: RAS CANCER BIOLOGY1. Ras and RASSF effector proteins / Jessica N. Mezzanotte and Geoffrey J. Clark2. Ras and the Hippo pathway in cancer / Eric O'Neill3. The Many Roles of RalGTPases in Ras-driven Cancer / David F. Kashatus4. The biology, prognostic relevance and targeted treatment of Ras pathway positive childhood acute lymphoblastic leukemia / Julie Anne Elizabeth Irving5. Oncogenic KRAS and the Inflammatory Microenvironment in Pancreatic Cancer / Hui-Hua Chang, Andrea Schmidt and Guido Eibl6. Activation of Ras by Post-Translational Modifications / Shengyan Xiang, Wenlong Bai, Gerold Bepler and Xiaohong Zhang7. Cross talk between Snail and mutant K-ras contributes to pancreatic cancer progression / Christina R. Chow, Kazumi Ebine, Holly Z. Hattaway, Krishan Kumar and Hidayatullah G. Munshi
SECTION II: NOVEL THERAPEUTIC APPROACHES TARGETING RAS AND RELATED PATHWAYS8. Search for Inhibitors of Ras-Driven Cancers / Adam B. Keeton and Gary A. Piazza9. GTP-competitive inhibitors of RAS family members / John C. Hunter and Kenneth D. Westover10. Next generation strategies to target RAF / Darrin D. Stuart11. Targeting metabolic vulnerabilities in Ras-mutant cells / Aparna D Rao and Grant A McArthur12. Blocking SIAH proteolysis, an important K-RAS vulnerability, to control and eradicate K-RAS-driven metastatic cancer / Robert Van Sciver, Monicah M. Njogu, Andrew J. Isbell, Justin J. Odanga, Minglei Bian, Elizaveta Svyatova, Lauren L. Siewertsz van Reesema, Vasilena Zheleva, Jamie L. Eisner, Jamie K. Bruflat, Rebecca L. Schmidt, Angela M. Tang-Tan, and Amy H. Tang13. Extracellular signal-regulated kinases (ERK1 and ERK2) Inhibitors / Ahmad Samatar14. Targeting Rho, Rac, CDC42 GTPase effector p21 activated kinases in cancer / Asfar Sohail Azmi; Philip A. Philip
SECTION II: NOVEL THERAPEUTIC APPROACHES TARGETING RAS AND RELATED PATHWAYS8. Search for Inhibitors of Ras-Driven Cancers / Adam B. Keeton and Gary A. Piazza9. GTP-competitive inhibitors of RAS family members / John C. Hunter and Kenneth D. Westover10. Next generation strategies to target RAF / Darrin D. Stuart11. Targeting metabolic vulnerabilities in Ras-mutant cells / Aparna D Rao and Grant A McArthur12. Blocking SIAH proteolysis, an important K-RAS vulnerability, to control and eradicate K-RAS-driven metastatic cancer / Robert Van Sciver, Monicah M. Njogu, Andrew J. Isbell, Justin J. Odanga, Minglei Bian, Elizaveta Svyatova, Lauren L. Siewertsz van Reesema, Vasilena Zheleva, Jamie L. Eisner, Jamie K. Bruflat, Rebecca L. Schmidt, Angela M. Tang-Tan, and Amy H. Tang13. Extracellular signal-regulated kinases (ERK1 and ERK2) Inhibitors / Ahmad Samatar14. Targeting Rho, Rac, CDC42 GTPase effector p21 activated kinases in cancer / Asfar Sohail Azmi; Philip A. Philip